Sorrento Therapeutics Inc (SRNE)

[dia76ca]

Sorrento is FOCUSED. It has 3 priority portfolios.
1.The immediate focus is Covid. It has 16 programs that deal with every stage of Covid. It already has one EUA with many to follow in the next few months. The latest C1 vaccine and oral MPro inhibitors have enormous potential. Each EUA will bring in a generous revenue stream.
2.The second area of focus is non-opioid pain. It already has a marketed product with sales projected to be about $100 million this year. SP-102 sales are expected in 2022 and are projected in the billions.
3. The longer term focus is cancer. Abivertinib sales in China could start any day and in ROW next year. ADNAB,CAR-T, DAR-T and several other technologies are targeting dozens of indications with many in phase two.
With hundreds of millions worth of very wise investments, many near-term potential worldwide partnerships, the large potential PSS lawsuit windfall and rapidly increasing revenue streams ... IMO Sorrento is very well funded to achieve success in all 3 priority portfolios!